secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2021-09-08T23:59:59+00:00
Accession:  0001193125-21-267331
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences appoints Jeanne Jew to Board of Directors, increasing board size to eight
--------------------------------------------------------------------------------

- Jeanne Y. Jew appointed as Class III director effective September 9, 2021, term expiring at 2024 annual meeting.
- Board increased from seven to eight members in connection with the appointment.
- Ms. Jew is Chief Business Officer of ALX Oncology since August 2020, with over 25 years of corporate development experience.
- She will receive standard non-employee director cash and equity compensation and enter an indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000119312521267331/0001193125-21-267331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000119312521267331/d228933d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-267331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer